ABSTRACT
In the face of the sudden outbreak of novel coronavirus pneumonia (coronavirusdisease-19, COVID-19), the research and development of new antiviral drugs requires a certain amount of time and cost, and it is urgent to find safe and effective antiviral drugs that can be used clinically. Lopinavir/ritonavir (lopinavir/ritonavir, LPV/r) is a commonly used antiviral drug against adult or child human immunodeficiency virus (humanimmunodeficiency, HIV) infections. Past animal trials and clinical experience suggest It is expected to have a certain anti-viral efficacy against the new coronavirus in the fight against severe acute respiratory syndrome (Severe acute respiratory syndrome, SARS) and Middle East respiratory syndrome (Midle East respiratory syndrome, MERS). drug. Especially for patients with mild infections, the combination of drugs seems to be expected to exert a better effect, but it is necessary to pay attention to the issue of drug safety and use drugs with caution. This article aims to review the clinical research progress of LPV/r anti-coronavirus infection treatment for clinical reference.